Abbott Laboratories (ABLD.XC)
Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
At close: 04:22PM BST
| Previous close | 95.04 |
| Open | 95.04 |
| Bid | 95.79 x 0 |
| Ask | 95.98 x 0 |
| Day's range | 95.04 - 95.04 |
| 52-week range | 87.58 - 104.98 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 167.249B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 32.00 |
| EPS (TTM) | 2.97 |
| Earnings date | 18 Jul 2024 - 22 Jul 2024 |
| Forward dividend & yield | 2.03 (2.14%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
ZacksAbbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) concluded the recent trading session at $103.95, signifying a -0.27% move from its prior day's close.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.